Abstrakt

Przypisy

• 1. Balcerczyk A., Bartosz G.: Thiols are main determinants of totalantioxidant capacity of cellular homogenates. Free Radic. Res.,2003; 37: 537-541
  Google Scholar
• 2. Böhm F., Pernow J.: The importance of endothelin-1 for vasculardysfunction in cardiovascular disease. Cardiovasc. Res., 2007; 76: 8-18
  Google Scholar
• 3. Boros M., Massberg S., Baranyi L., Okada H., Messmer K.: Endothelin 1 induces leukocyte adhesion in submucosal venules of therat small intestine. Gastroenterology, 1998; 114: 103-114
  Google Scholar
• 4. Briyal S., Philip T., Gulati A.: Endothelin-A receptor antagonistsprevent amyloid-β-induced increase in ETA receptor expression,oxidative stress, and cognitive impairment. J. Alzheimers Dis., 2011;23: 491-503
  Google Scholar
• 5. Comellas A.P., Briva A.: Role of endothelin-1 in acute lung injury.Transl. Res., 2009; 153: 263-271
  Google Scholar
• 6. Curtis T.M., Scholfield N.: Evidence for two endothelin EtA receptorsubtypes in rabbit arteriolar smooth muscle. Br. J. Pharmacol.,2001; 134: 1787-1795
  Google Scholar
• 7. Djukic M., Jovanovic M.D., Ninkovic M., Stevanovic I., Curcic M.,Topic A., Vujanovic D., Djurdjevic D.: Intrastriatal pre-treatmentwith L-NAME protects rats from diquat neurotoxcity. Ann. Agric.Environ. Med., 2012; 19: 666-672
  Google Scholar
• 8. Dobrek Ł., Thor P.: Endothelin in cardiovascular diseases pathophysiology.Pol. Merkur. Lekarski, 2010; 28: 289-292
  Google Scholar
• 9. Dorfman D.M., Wilson D.B., Bruns G.A., Orkin S.H.: Human transcriptionfactor GATA-2. Evidence for regulation of preproendothelin-1gene expression in endothelial cells. J. Biol. Chem., 1992;267: 1279-1285
  Google Scholar
• 10. Ellman G.L.: SH group determination in biological fluids. Anal.Biochem., 1970; 46: 233-235
  Google Scholar
• 11. Elmarakby A.A., Loomis E.D., Pollock J.S., Pollock D.M.: NADPHoxidase inhibition attenuates oxidative stress but not hypertensionproduced by chronic ET-1. Hypertension, 2005; 45: 283-287
  Google Scholar
• 12. Ergul A.: Endothelin-1 and endothelin receptor antagonistsas potential cardiovascular therapeutic agents. Pharmacotherapy,2002; 22: 54-65
  Google Scholar
• 13. Feldstein C., Romero C.: Role of endothelins in hypertension.Am. J. Ther., 2007; 14: 147-153
  Google Scholar
• 14. Fleming I., Busse R.: Molecular mechanisms involved in theregulation of the endothelial nitric oxide synthase. Am. J. Physiol.Regul. Integr. Comp. Physiol., 2003; 284: R1-R12
  Google Scholar
• 15. Hoeper M.M., Halank M., Marx C., Hoeffken G., Seyfarth H.J.,Schauer J., Niedermeyer J., Winkler J.: Bosentan therapy for portopulmonaryhypertension. Eur. Respir. J., 2005; 25: 502-508
  Google Scholar
• 16. Hoeper M.M., Seyfarth H.J., Hoeffken G., Wirtz H., SpiekerkoetterE., Pletz M.W., Welte T., Halank M.: Experience with inhaled iloprostand bosentan in portopulmonary hypertension. Eur. Respir.J., 2007; 30: 1096-1102
  Google Scholar
• 17. Huribal M., McMillen M.A.: Role of endothelin in ischemia-reperfusioninjury. Ann. N.Y. Acad. Sci., 1994; 723: 484-485
  Google Scholar
• 18. Hynynen M.M., Khalil R.A.: The vascular endothelin system inhypertension – recent patents and discoveries. Recent Pat. Cardiovasc.Drug Discov., 2006; 1: 95-108
  Google Scholar
• 19. Jakovljevic V.L., Djordjevic D.Z., Djuric D.M.: The effects of vitaminC and nitric oxide synthase inhibition on coronary flow andoxidative stress markers in isolated rat heart. Gen. Physiol. Biophys.,2011; 30: 293-300
  Google Scholar
• 20. Janas J., Sitkiewicz D., Januszewicz A., Szczesniak C., Grenda R.,Janas R.M.: Endothelin-1 inactivating peptidase in the human kidneyand urine. J. Hypertens., 2000; 18: 475-83
  Google Scholar
• 21. Kulbacka J., Saczko J., Chwiłkowska A.: Oxidative stress in cellsdamage processes. Pol. Merkur. Lekarski, 2009; 27: 44-47
  Google Scholar
• 22. Kun T., Dąbrowski R.: Endoteliny w regulacji funkcji układu krą-żenia. Pol. Przegl. Kardiol., 2002; 4: 149-155
  Google Scholar
• 23. Li L., Fink G.D., Watts S.W., Northcott C.A., Galligan J.J., PaganoP.J., Chen A.F.: Endothelin-1 increases vascular superoxide viaendothelin(A)-NADPH oxidase pathway in low-renin hypertension.Circulation, 2003; 107: 1053-1058
  Google Scholar
• 24. Masaki T., Miwa S., Sawamura T., Ninomiya H., Okamoto Y.: Subcellularmechanisms of endothelin action in vascular system. Eur. J.Pharmacol., 1999; 375: 133-138
  Google Scholar
• 25. Motte S., McEntee K., Naeije R.: Endothelin receptor antagonists.Pharmacol. Ther., 2006; 110: 386-414
  Google Scholar
• 26. Ohlstein E.H., Elliott J.D., Feuerstein G.Z., Ruffolo R.R.jr.: Endothelinreceptors: receptor classification, novel receptor antagonists,and potential therapeutic targets. Med. Res. Rev., 1996; 16: 365-390
  Google Scholar
• 27. Ozdemir R., Parlakpinar H., Polat A., Colak C., Ermis N., Acet A.:Selective endothelin a (ETA) receptor antagonist (BQ-123) reducesboth myocardial infarct size and oxidant injury. Toxicology, 2006;219: 142-149
  Google Scholar
• 28. Ponczek M.B., Wachowicz B.: Interaction of reactive oxygen andnitrogen species with proteins. Postępy Biochem., 2005; 51: 140-145
  Google Scholar
• 29. Ramprasath T., Kumar P.H., Puhari S.S., Murugan P.S., VasudevanV., Selvam G.S.: L-Arginine ameliorates cardiac left ventricularoxidative stress by upregulating eNOS and Nrf2 target genes inalloxan-induced hyperglycemic rats. Biochem. Biophys. Res. Commun.,2012; 428: 389-394
  Google Scholar
• 30. Resink T.J., Hahn A.W., Scott-Burden T., Powell J., Weber E.,Bühler F.R.: Inducible endothelin mRNA expression and peptide secretionin cultured human vascular smooth muscle cells. Biochem.Biophys. Res. Commun., 1990; 168: 1303-1310
  Google Scholar
• 31. Rosen B., Barg J., Zimlichman R.: The effects of angiotensin II,endothelin-1, and protein kinase C inhibitor on DNA synthesis and intracellular calcium mobilization in vascular smooth muscle cellsfrom young normotensive and spontaneously hypertensive rats.Am. J. Hypertens., 1999; 12: 1243-1251
  Google Scholar
• 32. Rubanyi G.M., Polokoff M.A.: Endothelins: molecular biology,biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol.Rev., 1994; 46: 325-415
  Google Scholar
• 33. Saravanakumar M., Raja B.: Veratric acid, a phenolic acid attenuatesblood pressure and oxidative stress in L-NAME inducedhypertensive rats. Eur. J. Pharmacol., 2011; 671: 87-94
  Google Scholar
• 34. Scalera F., Dittrich R., Beckmann M.W., Beinder E.: Effect of endothelin-1on intracellular glutathione and lipid peroxide availabilityand on the secretion of vasoactive substances by human umbilicalvein endothelial cells. Eur. J. Clin. Invest., 2002; 32: 556-562
  Google Scholar
• 35. Skalska A.B., Pietrzycka A., Stepniewski M.: Correlation of endothelin 1 plasma levels with plasma antioxidant capacity in elderlypatients treated for hypertension. Clin. Biochem., 2009; 42: 358-364
  Google Scholar
• 36. Thakali K., Demel S.L., Fink G.D., Watts S.W.: Endothelin-1-inducedcontraction in veins is independent of hydrogen peroxide.Am. J. Physiol. Heart Circ. Physiol., 2005; 289: H1115-H1122
  Google Scholar
• 37. Viswanatha Swamy A.H., Wangikar U., Koti B.C., ThippeswamyA.H., Ronad P.M., Manjula D.V.: Cardioprotective effect of ascorbicacid on doxorubicin-induced myocardial toxicity in rats. Indian J.Pharmacol., 2011; 43: 507-511
  Google Scholar
• 38. Weitzberg E., Rudehill A., Modin A., Lundberg J.M.: Porcine intrinsicpulmonary and systemic vascular tone is endothelin-dependent.Acta Physiol. Scand., 1994; 152: 433-434
  Google Scholar
• 39. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., KobayashiM., Mitsui Y., Yazaki Y., Goto K., Masaki T.: A novel potent vasoconstrictorpeptide produced by vascular endothelial cells. Nature,1988; 332: 411-415
  Google Scholar

Pełna treść artykułu